Physician
Centercare Family Practice, LLC
Centercare Family Practice, LLC was paid $2.99M by Medicaid between Jan 2018 and Dec 2024, across 80 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 31% of everything it billed.
33Billing provider infoCENTERCARE FAMILY PRACTICE, LLC
FREDERICKSBURG, VA 22401
FREDERICKSBURG, VA 22401
33aNPI1497106504assigned 06/29/2016
33bProvider typeFamily Medicine Physician
28Total paid$2.99M
24GClaims102,532
24DCodes billed80
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Virginia
Rank by total paid#12 of 772
Median peer was paid$13K
This provider vs. median228×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,615 | $142K | |
| 2019 | 13,770 | $368K | |
| 2020 | 16,880 | $454K | |
| 2021 | 16,876 | $442K | |
| 2022 | 17,769 | $491K | |
| 2023 | 19,544 | $656K | |
| 2024incomplete | 12,078 | $434K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 31% | 12,674 | 10,345 | $920K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 13,857 | 11,179 | $696K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 4.6% | 2,828 | 2,235 | $139K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.3% | 2,164 | 2,056 | $129K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.7% | 975 | 739 | $111K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.3% | 1,734 | 1,459 | $98K |
| 99050 | 2.3% | 8,927 | 7,559 | $68K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 1.8% | 837 | 798 | $53K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.7% | 6,837 | 5,486 | $49K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.6% | 4,472 | 1,972 | $47K |
| 90670 | 1.4% | 1,697 | 1,544 | $43K | |
| 90677 | 1.3% | 332 | 303 | $40K |
68 more codes
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 731 | $38K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.2% | 381 | $36K |
| 99381 | <1% | 609 | $29K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 479 | $29K |
| 90700 | <1% | 2,361 | $27K | |
| 90716 | <1% | 985 | $26K | |
| 87634 | <1% | 482 | $24K | |
| 90713 | <1% | 1,830 | $23K | |
| 87481 | <1% | 255 | $20K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 822 | $20K |
| 90680 | <1% | 1,024 | $19K | |
| 90707 | <1% | 994 | $19K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 6,578 | $19K |
| 90648 | <1% | 1,749 | $17K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,388 | $16K |
| 99401 | <1% | 1,176 | $16K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 465 | $16K |
| 92551 | <1% | 1,807 | $16K | |
| 90633 | <1% | 1,133 | $13K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 730 | $12K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 173 | $10K |
| 90744 | <1% | 946 | $10K | |
| 90686 | <1% | 904 | $10K | |
| 90651 | <1% | 175 | $9K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 866 | $9K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 233 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 700 | $9K |
| 99072 | <1% | 2,302 | $7K | |
| 87807 | <1% | 560 | $6K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 80 | $6K |
| 87640 | <1% | 253 | $5K | |
| 87653 | <1% | 253 | $5K | |
| 99383 | <1% | 69 | $5K | |
| 99173 | <1% | 2,415 | $5K | |
| 90619 | <1% | 106 | $5K | |
| 90461 | <1% | 3,522 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 313 | $4K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 186 | $3K |
| 87581 | <1% | 122 | $3K | |
| 87486 | <1% | 122 | $3K | |
| 99382 | <1% | 57 | $3K | |
| 90698 | <1% | 179 | $3K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,354 | $2K |
| 87500 | <1% | 93 | $2K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 40 | $2K |
| 99386 | <1% | 17 | $2K | |
| 99188 | <1% | 98 | $2K | |
| 96160 | <1% | 898 | $2K | |
| 90734 | <1% | 83 | $2K | |
| 81002 | <1% | 558 | $1K | |
| 90715 | <1% | 75 | $1K | |
| 99385 | <1% | 14 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 303 | $1K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 128 | $844.04 |
| 83655 | <1% | 75 | $775.08 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 103 | $389.61 |
| 90685 | <1% | 32 | $333.79 | |
| 93000 | <1% | 26 | $328.29 | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 138 | $274.00 |
| 90656 | <1% | 17 | $210.05 | |
| A7003 | Administration set, with small volume nonfiltered pneumatic nebulizer, disposable | <1% | 146 | $150.33 |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 143 | $129.16 |
| 99001 | <1% | 100 | $22.08 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 95 | $8.55 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 14 | $8.13 |
| 94760 | <1% | 39 | $6.56 | |
| J7699 | Noc drugs, inhalation solution administered through dme | <1% | 13 | $3.75 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 81 | $2.79 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAURORE, MICKELINA (MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Pedsplus Urgent Care, LLC | Fredericksburg, VA | $11.03M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.